

CORRECTION



Correction: Comparative Assessment of Drug Lag for Approved Oncology Targeted Therapies Between Saudi Arabia, the United States, and the European Union

Mohammed Alnuhait¹ · Abdullah Alshammari¹ · Manar Alharbi¹ · Lina Alotaibi¹ · Reem Alharbi¹ · Attiah Khobrani² · Nora Alkhudair³ · Majed Alshamrani⁴ · Abdullah M. Alrajhi^{5,6}

© The Author(s), under exclusive licence to The Drug Information Association, Inc 2024

Therapeutic Innovation & Regulatory Science

<https://doi.org/10.1007/s43441-024-00642-5>

In the published article a portion of Fig. 1 was missing. The corrected figure follows:

The online version of the original article can be found at <https://doi.org/10.1007/s43441-024-00642-5>.

✉ Mohammed Alnuhait
manuhait@uqu.edu.sa

Abdullah Alshammari
asshammari@uqu.edu.sa

Manar Alharbi
s438010174@st.uqu.edu.sa

Lina Alotaibi
s439001685@st.uqu.edu.sa

Reem Alharbi
s439000467@st.uqu.edu.sa

Attiah Khobrani
khobrani.a@kamc.med.sa

Nora Alkhudair
noura.alkhudair@gmail.com

Majed Alshamrani
shamranima01@ngha.med.sa

Abdullah M. Alrajhi
abdullahalrajhi335@gmail.com

¹ Clinical Pharmacy Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia


² Pharmaceutical Care Services, King Abdullah Medical City, Makkah, Saudi Arabia

³ Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia

⁴ Department of Pharmaceutical Care Services, King Abdulaziz Medical City (KAMC), Jeddah, Saudi Arabia

⁵ Clinical Pharmacy Department, King Fahad Medical City, Riyadh, Saudi Arabia

⁶ Department of Pharmacy Practice, College of Pharmacy, AlFaisal University, Riyadh, Saudi Arabia



Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.